BK Medical and Varian Medical Systems Collaborate to Streamline Prostate Brachytherapy Treatments
Varian Medical Systems zu myNews hinzufügen Was ist das?
BK Medical, a wholly owned subsidiary of Analogic Corporation
(NASDAQ:ALOG), and Varian Medical Systems (NYSE:VAR) today announced a
global collaboration to improve and streamline prostate brachytherapy
procedures through a new, digital interface between BK Medical’s
Pro Focus ultrasound scanner and Varian’s
VariSeed 8.0 planning software.
This new digital interface enables new ways of performing prostate
brachytherapy with its easy-to-use, streamlined workflow capabilities
that include automatic calibration and multiple contouring transfers.
Brachytherapy is an effective and widely used weapon in the armory of
oncologists in the fight against prostate cancer.
"This confirms the commitment of our two companies to pioneer innovative
medical solutions,” says Michael Brock, BK
Medical’s president. "Our
market-leading positions give us a unique opportunity to keep up to date
with, and respond to, our customers’ evolving
needs. That BK and Varian can combine their high-quality products and
customer solutions is a clear advantage for our customers and their
patients."
"This interface gives us a much higher quality
image transfer and enables VariSeed to be far more interactive with the
ultrasound unit,” says Hosea Mitchell, head of
Varian’s brachytherapy group. "We
are delighted to be working closely with BK Medical to help our
customers deliver treatments more efficiently.”
These efficiency improvements include improved workflow, as the image
calibration data and contours are sent directly from the ultrasound to
VariSeed so the user does not need to calibrate the images or re-contour
the structures, thereby saving time. The new interface also offers
greater flexibility, as the urologist or radiation oncologist can zoom
in or out on the ultrasound while using the VariSeed intra-operative
module (Implant View) without losing calibration between the two systems.
BK Medical and Varian will be co-presenting the new interface at the
upcoming 2008 World Congress of Brachytherapy, May 4 - 6, in Boston,
Mass., followed by the 2008 American Urological Association meeting, May
17-22, in Orlando, Fla.
Facts about BK Medical
BK Medical ApS, a wholly owned subsidiary of Analogic Corporation
(NASDAQ:ALOG), specializes in the development and production of
diagnostic ultrasound equipment. The company is recognized as a world
leader in developing ultrasound scanners specially designed for surgery
and for the investigation of urological disorders. The product line also
includes scanners for other applications, such as gynecological
examinations, fetal scanning, and radiology.
BK Medical is represented in 60 countries, with subsidiary sales
companies in the U.S., Belgium, Germany, Italy, Norway, Sweden and the
U.K. An extensive network of distributors connects B-K Medical with
Eastern Europe, the Middle East, Asia and the rest of the world. The
company has about 300 employees, of which about two-thirds are located
in Denmark. For more information, visit http://www.bkmed.com/.
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world’s
leading manufacturer of medical devices and software for treating cancer
and other medical conditions with radiotherapy, radiosurgery, proton
therapy, and brachytherapy. The company supplies informatics software
for managing comprehensive cancer clinics, radiotherapy centers and
medical oncology practices. Varian is a premier supplier of tubes and
digital detectors for X-ray imaging in medical, scientific, and
industrial applications and also supplies X-ray imaging products for
cargo screening and industrial inspection. Varian Medical Systems
employs approximately 4,600 people who are located at manufacturing
sites in North America and Europe and in its 60 sales and support
offices around the world. For more information, visit http://www.varian.com/.
Forward Looking Statements
Statements in this press release regarding future business, events,
plans, objectives, expectations, estimates, and other similar matters,
including, but not limited to, statements using the terms "can" and
"expect," constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements contained in this press release are subject
to risks and uncertainties that could cause actual results to differ
materially from those anticipated, including, but not limited to, the
risks described in the company's Annual Report on Form 10-K and other
reports filed from time to time by the Company with the Securities and
Exchange Commission. These forward-looking statements represent the
Company's judgment as of the date of this press release. The Company
assumes no obligation to update or revise these forward-looking
statements because of new information, future events, or otherwise.
